Testing a new kidney cancer drug alone and with other treatments

Plain-English translation of NCT07293351 on ClinicalTrials.gov ↗ · Source last updated September 2026 · Translation generated October 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a new drug called to treat advanced kidney cancer (renal cell carcinoma). Researchers want to see if the medication works better when given by itself or when combined with other approved cancer drugs. The study will measure how safe the treatment is, how well patients tolerate it, and whether it helps shrink or control the cancer.

Current treatments for advanced kidney cancer don't work for everyone, and some patients develop resistance over time. This trial is exploring whether this medication can offer a new option, either as a standalone therapy or paired with existing drugs, to help more patients with this serious disease.

Do you qualify?

You likely qualify if…

you have been diagnosed with locally advanced, unresectable, or metastatic renal cell carcinoma (kidney cancer) that is confirmed by biopsy
you have clear cell or non-clear cell kidney cancer (depending on which part of the study you join)
you have measurable disease that can be seen on imaging scans
you have not previously received systemic (whole-body) chemotherapy or immunotherapy for metastatic kidney cancer, though some prior treatments may be allowed depending on the study arm
you are able to travel for study visits and follow the study schedule

You likely don't qualify if…

you have untreated brain metastases (cancer that has spread to the brain)
you have a history of lung inflammation, blood clots, or serious heart disease within the last 6 months
you are currently taking high-dose steroids or medications that suppress your immune system
you have had major surgery or significant trauma within the last 4 weeks
you have uncontrolled high blood pressure or abnormal protein levels in your urine

What participation looks like

Participants will receive the medication as part of one of several treatment groups — either the new drug alone or combined with one or more existing cancer therapies. You'll have regular clinic visits for blood tests, imaging scans, and check-ups to monitor how the treatment is working and how you're tolerating it. The study involves multiple phases to first test safety and then expand to larger groups, so your commitment will span several months with frequent monitoring.

AI-generated summary from trial data · Oct 4, 2026 · Not medical advice

Trial locations(95 sites)

United States

Local Institution - 0178, Palo Alto, California

Local Institution - 0117, New Haven, Connecticut

Sibley Memorial Hospital, Washington D.C., District of Columbia

Local Institution - 0177, Miami, Florida

Local Institution - 0126, Orlando, Florida